Chiusura precedente | 3,33 |
Aperto | 2,11 |
Denaro | 0,00 x N/D |
Lettera | 0,00 x N/D |
Min-Max giorno | 2,10 - 2,11 |
Intervallo di 52 settimane | 2,10 - 2,11 |
Volume | |
Media Volume | N/D |
Capitalizzazione | N/D |
Beta (5 anni mensile) | 0,81 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,14 |
Prossima data utili | 09 giu 2022 |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
Third quarter revenue of $26.2 million declined sequentially and year over year due to the anticipated waning of COVID-19 volumes and the economic shutdowns in Asia Received approval from New York State Department of Health for its AMPIPROBE® HPV Molecular Diagnostic tests available on the GENFLEX® platform, as well as approvals on additional sample types around chlamydia, gonorrhea and trichomonas Appointed and hired several new executive management team members in the quarter to position the C
Conference Call and Webcast Scheduled for June 10, 2022, 8:30 am ETNEW YORK, NY, June 06, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report third quarter 2022 financial results on Thursday, June 9, 2022, after the market close. The announcement will be followed by a live audio webcast and conference call on Friday, June 10, 2022 at 8:30 am Eastern Time. Please see additional details below: Friday, June 10th
Conference Call and Webcast Scheduled for June 9, 2022, 4:30 pm ET NEW YORK, NY, June 02, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report third quarter 2022 financial results on Thursday, June 9, 2022, after the market close. The announcement will be followed by a live audio webcast and conference call at 4:30 pm Eastern Time. Thursday, June 9th @ 4:30 pm ETDomestic: 877-407-0792International: 201-689-8263